Clinical, metabolic, and immunological characterisation of adult Ugandan patients with new-onset diabetes and low vitamin D status

Davis Kibirige1,2*, Isaac Sekitoleko1, Priscilla Balungi1,3, Jacqueline Kyosimire-Lugemwa3 and William Lumu4

Abstract

Background: Low vitamin D concentrations are associated with metabolic derangements, notably insulin resistance and pancreatic beta-cell dysfunction in Caucasian populations. Studies on its association with the clinical, metabolic, and immunologic characteristics in black African adult populations with new-onset diabetes are limited. This study aimed to describe the clinical, metabolic, and immunologic characteristics of a black Ugandan adult population with recently diagnosed diabetes and hypovitaminosis D.

Methods: Serum vitamin D concentrations were measured in 327 participants with recently diagnosed diabetes. Vitamin D deficiency, vitamin D insufficiency, and normal vitamin D status were defined as serum 25 hydroxyvitamin D levels of < 20 ng/ml, 21–29 ng/ml, and ≥ 30 ng/ml, respectively.

Results: The median (IQR) age, glycated haemoglobin, and serum vitamin D concentration of the participants were 48 years (39–58), 11% (8–13) or 96 mmol/mol (67–115), and 24 ng/ml (18–30), respectively. Vitamin D deficiency, vitamin D insufficiency, and normal vitamin D status were noted in 105 participants (32.1%), 140 participants (42.8%), and 82 participants (25.1%), respectively.

Compared with those having normal serum vitamin D levels, participants with vitamin D deficiency and insufficiency had higher circulating concentrations of interleukin (IL) 6 (29 [16–45] pg/ml, 23 [14–40] pg/ml vs 18 [14–32] pg/ml, \( p = 0.01 \)), and IL-8 (24 [86–655] pg/ml, 207 [81–853] pg/ml vs 98 [67–224], \( p = 0.03 \)). No statistically significant differences were noted in the markers of body adiposity, insulin resistance, and pancreatic beta-cell function between both groups.

Conclusion: Vitamin D deficiency and insufficiency were highly prevalent in our study population and were associated with increased circulating concentrations of pro-inflammatory cytokines. The absence of an association between pancreatic beta-cell function, insulin resistance, and low vitamin D status may indicate that the latter does not play a significant role in the pathogenesis of type 2 diabetes in our adult Ugandan population.

*Correspondence: kibirigedavis@gmail.com

1 Non-Communicable Diseases Program, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, P.O. BOX 49, Plot 51-59, Nakiwogo Road, Entebbe, Uganda

Full list of author information is available at the end of the article
Background
Globally, vitamin D deficiency and insufficiency remain highly prevalent in most populations, posing significant public health challenges. The prevalence greatly varies across different populations, and this may be attributed to the differences in geographical location (proximity to the equator), seasons (tropical seasons versus prolonged winter periods), obesity, culture, lifestyle (diet and clothing), and skin pigmentation [1–3].

Despite the presence of abundant sunshine all year round in most parts of Africa, the frequency of vitamin D deficiency and insufficiency remains very high [4, 5]. A recent systematic review and meta-analysis that evaluated the burden of vitamin D deficiency in Africa reported a pooled analysis of low vitamin D status of 59.5%, based on a serum vitamin D cut-off of < 75 nmol/l (30 ng/ml) [4]. This high burden of hypovitaminosis D in Africa may be due to dietary reasons (low dietary calcium and vitamin D intake), high prevalence of communicable diseases like HIV infection, cultural and religious practices (full-body clothing style), and dark skin pigmentation, which directly affect vitamin D absorption and biosynthesis.

In addition to having a significant role in bone and mineral metabolism, vitamin D is also integral in maintaining optimal glucose homeostasis, pancreatic beta-cell function, and an anti-inflammatory milieu [6]. In Caucasian and Asian populations, low vitamin D concentrations have been shown to increase the risk of type 2 diabetes, prediabetes, an adverse cardiometabolic and inflammatory profile (increased insulin resistance, obesity, hypertension, atherogenic lipid profile, and a pro-inflammatory state), and diabetes complications [7–17].

Despite the high prevalence of low vitamin D status in adult populations in sub-Saharan Africa (SSA), studies on the clinical, metabolic, and immunologic characterisation of adult patients with newly diagnosed diabetes and vitamin D deficiency and insufficiency are limited. To address this gap, we undertook this multi-center study to determine the burden of vitamin D deficiency and insufficiency in an adult black Ugandan population with recently diagnosed diabetes and also describe the associated clinical, metabolic, and immunologic characteristics.

Methods
Study sites and duration
All participants were recruited from outpatient diabetes clinics of seven tertiary public and private not-for-profit (PNFP) mission or church-founded hospitals located in Kampala (central Uganda) and Masaka (Southwestern Uganda) districts. The latitudes and longitudes of these districts are 0.3476° N / 32.5825° E and 0.4464° S / 31.9018° E, respectively. These hospitals serve urban, peri-urban, and rural populations and run once-weekly specialist outpatient adult diabetes clinics where patients receive long-term diabetes care. Recruitment of participants was carried out from February 2019 to October 2020.

Study participants
A total of 327 participants aged ≥ 18 years with a recent diagnosis of diabetes made within the preceding three months were recruited from the outpatient adult diabetes clinics. We recruited participants who were either on glucose-lowering therapy or treatment naïve, regardless of the type of diabetes.

Before recruitment, the diagnosis of diabetes would have been made by clinicians at the various general outpatient clinics based either on a fasting blood glucose (FBG) concentration ≥ 7 mmol/l, random blood glucose concentration ≥ 11.1 mmol/l with signs and symptoms suggestive of hyperglycaemia, or glycated haemoglobin (HbA1c) concentration ≥ 6.5% (48 mmol/mol) as recommended by the World Health Organisation guidelines on the diagnosis of diabetes [18].

All recruited study participants were black indigenous Ugandans. We excluded pregnant women from this study.

Assessment of socio-demographic, clinical, biophysical, and metabolic characteristics
Using a pre-tested case report form, specific sociodemographic (age at diagnosis, sex, residence), clinical (medical comorbidities: hypertension and HIV infection), and anthropometric (weight, height, body mass index or BMI, waist circumference or WC, hip circumference or HC, and waist: hip circumference ratio or WHR) characteristics of interest were obtained from all participants. The total body fat level was evaluated using bioimpedance analysis (BIA) with an OMRON® BF511 body composition monitor (Omron Healthcare Co., Ltd, Tokyo Japan).

Following an overnight fast of a minimum of eight hours, a venous blood sample was drawn for measurement of fasting blood glucose (FBG), insulin, C-peptide, lipid profile, glycated haemoglobin (HbA1c), 25 hydroxyvitamin D, and a panel of inflammatory

Keywords: Vitamin D deficiency, Vitamin D insufficiency, Newly diagnosed diabetes, African population, Uganda, Sub-Saharan Africa
cytokines (interleukin [IL]-1β, IL-6, IL-8, and tumour necrosis factor-α or TNF-α).

The blood samples were collected in serum separating tubes (SST) II and ethylenediamine tetra-acetic acid (EDTA) tubes and immediately kept at 3 °C and room temperature, respectively at each study site before being transported to the clinical chemistry laboratory. On arrival at the clinical chemistry laboratory, the samples were aliquoted and stored at -80 °C until laboratory analysis was performed.

All the above laboratory tests were performed within three days of sample collection at the ISO-certified clinical chemistry laboratory at Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe Uganda using electro-chemiluminescence immunoassays manufactured by Roche diagnostics Limited, Germany on a Cobas 6000 C-model SN 14H3-15 machine (Hitachi High Technologies Corporation, Tokyo Japan).

Serum vitamin D (25 hydroxyvitamin D) concentrations were measured using the Elecsys® Roche diagnostics electrochemiluminescence binding assay (Roche Diagnostics, Mannheim, Germany). The assay has been shown in several studies to have comparative analytical performance with the well-established standardised methods of vitamin D assessment such as high-performance liquid chromatography and liquid chromatography with tandem mass spectrometry (LC–MS/MS) [19–22].

It has a measuring range of 3–100 ng/ml (7.5–250 nmol/l) and uses a vitamin D binding protein as capture protein which binds to both 25-hydroxyvitamin D2 and D3. The precision studies performed using repeated control measurements gave an imprecision value of <10%. The calibration was performed using Roche standard calibrator which is traceable to the LC–MS/MS. Accuracy studies performed by the manufacturer and LC–MS/MS gave a correlation value of \( R = 0.894 \) for sample concentrations ranging between 3–81 ng/ml (7.5–203) nmol/L.

The inflammatory cytokines were measured using a 7-plex human magnetic Luminex® assay from R&D Systems, Inc, Minneapolis, MN, US.

The online homeostatic model assessment-2 (HOMA2) calculator by the Diabetes Trial Unit of the University of Oxford, UK was used to calculate the insulin resistance (HOMA2-IR) and the pancreatic beta-cell function (HOMA2-%B) [23]. We also assessed pancreatic beta-cell function using oral insulinogenic index (IGI) which was derived using the formula: IGI = difference between the serum insulin concentration at the 30-min and 0-min time point/difference between the glucose concentration at the 30-min and 0-min time point [24].

Definition of vitamin D status
Vitamin D deficiency, vitamin D insufficiency, and normal vitamin D status were defined according to the Endocrine Society clinical practice guideline as serum vitamin D levels <20 ng/ml, 21–29 ng/ml, and ≥30 ng/ml, respectively [25].

Sample size estimation
Using the Leslie Kish formula (1965. Survey Sampling, New York: John Wiley and Sons, Inc.) of sample size calculation for cross-sectional studies, \( n = Z^2Pq/d^2 \) where \( n = \) sample size, \( Z = 1.96 \), the normal value corresponding to the 95% confidence interval, \( d = 5\% \) as the margin of error and a prevalence (P) of vitamin D deficiency of 71.1% in 124 adult patients with type 2 diabetes attending an outpatient diabetes clinic in Western Kenya [26], we estimated a sample size of a minimum of 316 participants.

Statistical analysis
The categorical and continuous variables describing the study participants were expressed as percentages and medians with inter-quaritle range (IQR), respectively. The prevalence of vitamin D deficiency, vitamin D insufficiency, and normal vitamin D status was expressed as percentages. The differences in the socio-demographic, clinical, anthropometric, metabolic, and immunologic characteristics of participants with vitamin D deficiency, vitamin D insufficiency, and normal vitamin D status were analysed using the \( \chi^2 \) test for categorical data and the Kruskal Wallis test for continuous data. All analyses were done using STATA statistical software version 15 College Station (StataCorp, US). A \( p \)-value < 0.05 was considered statistically significant.

Ethical approval
The study was performed in accordance with the Declaration of Helsinki. This study was approved by the Research Ethics Committee of the Uganda Virus Research Centre, Entebbe Uganda (GC/127/18/05/650) and the Uganda National Council of Science and Technology (HS 2431). Administrative approval was also obtained from all participating study sites. All enrolled study participants provided written informed consent to participate in the study.

Results
Baseline characteristics of all study participants
The socio-demographic, clinical, anthropometric, metabolic, and immunologic characteristics of all study participants are summarised in Table 1.

The median (IQR) age, BMI, HbA1c, and vitamin D concentration of the participants was 48 years (39–58),
Vitamin D status of the study participants
Vitamin D deficiency, vitamin D insufficiency, and normal vitamin D status were noted in 105 participants (32.1%), 140 participants (42.8%), and 82 participants (25.1%), respectively. Female participants had statistically lower serum vitamin D concentrations compared with male participants (23 [18–29] ng/ml vs 24 [19–32] ng/ml, $p = 0.05$).

Socio-demographic, clinical, anthropometric, metabolic, and immunologic characteristics of participants with vitamin D deficiency, insufficiency, and normal vitamin D status
The socio-demographic, clinical, anthropometric, metabolic, and immunologic characteristics of participants with vitamin D deficiency, vitamin D insufficiency, and normal vitamin D status are also summarised in Table 1.

Compared with those with normal vitamin D status, participants with vitamin D deficiency and insufficiency had higher circulating concentrations of interleukin (IL) 6 (29 [16–45] pg/ml, 23 [14–40] pg/ml vs 18 [14–32] pg/ml, $p = 0.01$), and IL-8 (24 [86–655] pg/ml, 207 [81–853] pg/ml vs 98 [67–224], $p = 0.03$) (Fig. 1).

No statistically significant differences were noted in age at diagnosis, glycaemic and insulin indices (FBG, HbA1c, fasting insulin concentration), HOMA2-IR, and measures of metabolic syndrome (WC, systolic and diastolic blood pressure, serum triglycerides), and pancreatic beta-cell function (fasting C-peptide, oral insulinogenic index, and HOMA2-%B) between the two categories.

Regarding markers of pancreatic beta-cell function, the male participants had lower markers of pancreatic beta-cell function compared with the female participants (oral insulinogenic index: 0.9 [0.3–2.7] µU/mmol vs 1.7 [0.6–4.6] µU/mmol, $p < 0.001$ and fasting C-peptide: 1.2 [0.8–2.0] ng/ml vs 1.5 [0.9–2.2] ng/ml, $p = 0.01$). No statistical difference in the HOMA2-IR was observed across both genders (males-1.2 [0.8–2.0] vs females-1.3 [0.8–2.1], $p = 0.08$).

Discussion
To the best of our knowledge, this is the first study to investigate the burden of vitamin D deficiency and insufficiency in an adult population with recently diagnosed diabetes in Uganda, a tropical country with abundant sunshine all year round. The study demonstrates that low vitamin D status is highly prevalent in our adult population with newly diagnosed diabetes and is associated with increased circulating concentrations of specific pro-inflammatory cytokines.

A high frequency of low vitamin D status has been widely reported by studies conducted in most sub-Saharan African populations with type 2 diabetes. The prevalence of vitamin D deficiency observed in our study is almost similar to what was reported by a study performed on 150 adult patients with long-standing type 2 diabetes attending an outpatient diabetes clinic in a tertiary public hospital in Nairobi, Kenya (38.4%) [27]. Another similar study performed on an adult population with long-standing type 2 diabetes in Western Kenya reported a higher prevalence of vitamin D deficiency of 71.1% [26]. A high prevalence of vitamin D deficiency has also been reported in adult Nigerian (63.2%) [28] and Ghanaian (92.4%) [29] populations with long-standing type 2 diabetes. All of these studies reported a lower prevalence of vitamin D insufficiency compared with what we documented in our study.

The variation in the prevalence of hypovitaminosis D in these adult African populations with type 2 diabetes may be explained by the differences in geographical location (proximity to the equator), dietary patterns (low vitamin D diets), local cultural and religious practices (especially related to full-body clothing style), obesity or overweight, and effect of co-infections especially communicable diseases like tuberculosis and HIV.

The differences between the burden of vitamin D deficiency reported in our study and other African studies should be interpreted with caution because we recruited patients with a recent diagnosis of diabetes as opposed to patients with long-standing diabetes. Increasing the duration of diabetes may directly or indirectly affect the frequency of hypovitaminosis D due to the related dietary restrictions (low dietary intake of calcium and vitamin D-rich foods), increased adiposity, and comorbidities like chronic liver and renal dysfunction.

Participants with vitamin D deficiency and insufficiency had higher median concentrations of circulating pro-inflammatory cytokines (IL-6, and IL-8) compared with those with normal vitamin D concentrations, indicating that low vitamin D levels are associated with a chronic low-grade pro-inflammatory state. This inverse relationship between vitamin D concentrations and circulating pro-inflammatory cytokines has also been reported in other studies [30, 31].

Vitamin D is a potent immunomodulator and its receptors are widely expressed on most immune cells especially antigen-presenting cells (macrophages and dendritic cells) and activated T-cells [32]. Vitamin D has been shown to inhibit dendritic cell maturation and function and...
Table 1  Socio-demographic, clinical, metabolic, and immunologic characteristics of all study participants, and those with vitamin D deficiency, insufficiency, and normal vitamin D status

| Characteristics                                      | All study participants (n = 327) | Vitamin D deficient (n = 105, 32.1%) | Vitamin D insufficient (n = 140, 42.8%) | Normal Vitamin D status (n = 82, 25.1%) | P-value |
|------------------------------------------------------|---------------------------------|-------------------------------------|----------------------------------------|----------------------------------------|---------|
| **Socio-demographic and clinical**                   |                                 |                                     |                                        |                                        |         |
| Age (years)                                          | 48 (39–58)                      | 47 (38–56)                          | 47 (39–59)                             | 50 (40–57)                             | 0.13    |
| Sex                                                  |                                 |                                     |                                        |                                        |         |
| Males                                                | 150 (46)                        | 44 (42)                             | 63 (45)                                | 43 (52)                                | 0.34    |
| Females                                              | 177 (54)                        | 61 (58)                             | 77 (55)                                | 39 (48)                                |         |
| Residence\(^a\)                                       |                                 |                                     |                                        |                                        |         |
| Urban                                                | 234 (72)                        | 74 (70)                             | 98 (70)                                | 62 (76)                                | 0.42    |
| Rural                                                | 92 (28)                         | 31 (30)                             | 42 (30)                                | 19 (23)                                |         |
| Hypertension comorbidity                             | 110 (34)                        | 36 (34)                             | 42 (30)                                | 32 (39)                                | 0.38    |
| HIV co-infection                                      | 39 (12)                         | 17 (16)                             | 10 (7)                                 | 12 (15)                                | 0.07    |
| Glucose-lowering therapy initiated\(^b\)              |                                 |                                     |                                        |                                        |         |
| Insulin                                               | 90 (28)                         | 36 (34)                             | 32 (23)                                | 22 (27)                                | 0.14    |
| Sulfonylureas                                         | 130 (40)                        | 37 (35)                             | 60 (43)                                | 33 (40)                                | 0.48    |
| Metformin                                             | 257 (79)                        | 76 (72)                             | 116 (83)                               | 65 (79)                                | 0.14    |
| Systolic blood pressure, mmHg                         | 126 (114–137)                   | 125 (112–136)                       | 126 (113–136)                          | 127 (115–139)                          | 0.53    |
| Diastolic blood pressure, mmHg                        | 83 (77–90)                      | 82 (76–90)                          | 84 (77–90)                             | 84 (78–92)                             | 0.23    |
| Waist circumference, cm                               | 95 (87–104)                     | 96 (85–102)                         | 95 (89–105)                            | 94 (87–104)                            | 0.66    |
| Hip circumference, cm                                 | 102 (95–111)                    | 102 (94–110)                        | 103 (96–111)                           | 103 (96–112)                           | 0.49    |
| Body fat level, %                                     | 35 (24–45)                      | 36 (25–43)                          | 38 (25–45)                             | 31 (23–45)                             | 0.29    |
| Body mass index, kg/m\(^2\)                          | 27 (23–31)                      | 26 (23–31)                          | 28 (24–31)                             | 26 (24–31)                             | 0.81    |
| Waist: hip circumference ratio                        | 0.9 (0.9–1.0)                   | 0.9 (0.9–1.0)                       | 0.9 (0.9–1.0)                          | 0.9 (0.9–1.0)                          | 1.00    |
| **Metabolic**                                         |                                 |                                     |                                        |                                        |         |
| TC, mmol/l                                           | 4.0 (3.2–4.8)                   | 4.2 (3.2–4.8)                       | 3.8 (3.3–4.9)                          | 3.8 (3.2–4.7)                          | 0.06    |
| HDLc, mmol/l                                         | 0.9 (0.7–1.2)                   | 0.9 (0.7–1.2)                       | 0.9 (0.7–1.2)                          | 0.9 (0.7–1.2)                          | 0.46    |
| TGL, mmol/l                                          | 1.4 (1.0–1.8)                   | 1.5 (1.1–2.1)                       | 1.4 (1.0–1.8)                          | 1.3 (0.9–1.7)                          | 0.08    |
| LDLc, mmol/l                                         | 2.5 (2.0–3.3)                   | 2.6 (1.8–3.4)                       | 2.5 (2.0–3.4)                          | 2.5 (2.0–3.1)                          | 0.91    |
| Non-HDLc, mmol/l                                     | 2.9 (2.3–3.7)                   | 3.1 (2.3–3.8)                       | 2.9 (2.3–3.7)                          | 2.9 (2.3–3.7)                          | 0.45    |
| TC/HDLc                                              | 4.3 (3.4–5.4)                   | 4.4 (3.4–5.7)                       | 4.3 (3.4–5.2)                          | 4.2 (3.3–5.3)                          | 0.56    |
| HbA1c, %                                              | 11 (8–13)                       | 11 (9–13)                           | 11 (9–13)                              | 10 (7–13)                              | 0.10    |
| HbA1c, mmol/mol                                       | 96 (67–115)                     | 99 (72–120)                         | 95 (70–113)                            | 86 (56–119)                            | 0.10    |
| Fasting serum insulin, µU/ml                          | 5.5 (2.8–9.4)                   | 5.7 (2.4–9.4)                       | 5.5 (2.9–9.5)                          | 5.3 (2.8–8.8)                          | 0.71    |
| Fasting serum C-peptide, ng/ml                        | 1.3 (0.7–1.9)                   | 1.2 (0.6–2.0)                       | 1.3 (0.8–1.8)                          | 1.3 (0.9–1.9)                          | 0.63    |
| Fasting blood glucose, mmol/l                         | 9.0 (6.5–13.6)                  | 10.4 (7.0–15.1)                     | 8.7 (6.6–12.9)                         | 8.6 (6.1–11.9)                         | 0.16    |
| HOMA2-IR                                              | 1.2 (0.8–1.9)                   | 1.3 (0.9–1.8)                       | 1.1 (0.7–1.7)                          | 1.0 (0.7–2.5)                          | 0.22    |
| HOMA2-%B                                              | 38 (18–67)                      | 34 (16–64)                          | 44 (24–67)                             | 38 (18–72)                             | 0.19    |
| Oral IGI, µU/ml/mmol                                  | 1.1 (0.4–3.2)                   | 1.0 (0.4–2.4)                       | 1.2 (0.5–3.3)                          | 1.1 (0.4–5.0)                          | 0.82    |
| **Immunologic**                                       |                                 |                                     |                                        |                                        |         |
| IL-1 β, pg/ml                                         | 16 (14–20)                      | 16 (14–20)                          | 16 (14–20)                             | 15 (14–19)                             | 0.17    |
| IL-6, pg/ml                                           | 26 (15–41)                      | 29 (16–45)                          | 23 (14–40)                             | 18 (14–32)                             | 0.01    |
| IL-8, pg/ml                                           | 186 (76–577)                    | 242 (86–655)                        | 207 (81–853)                           | 98 (67–224)                            | 0.03    |
| TNF-α, pg/ml                                          | 24 (19–33)                      | 25 (20–33)                          | 24 (20–33)                             | 22 (18–30)                             | 0.10    |

\(^a\) Missing data of one participant in the normal vitamin D status group

\(^b\) Therapy initiated either as monotherapy or in combination

\(HbA1c\) Glycated haemoglobin, \(HDLC\) High dense lipoprotein cholesterol, \(HOMA2-%B\) Homeostatic model assessment 2-beta cell function, \(HOMA2-IR\) Homeostatic model assessment 2- insulin resistance, \(IL\) Interleukin, \(LDLC\) Low dense lipoprotein cholesterol, \(TC\) Total cholesterol, \(TGL\) Triglycerides, \(TNF\) Tumour necrosis factor
macrophage differentiation in addition to inhibition of proliferation and differentiation of CD4 cells into T-helper 1 (Th1) and T-helper 7 (Th7) cells. It has also been shown to downregulate the secretion of several pro-inflammatory cytokines like IL-2, IL-6, and TNF-α [33].

Low vitamin D status, therefore, is associated with a Th1 and Th7 pro-inflammatory cytokine profile as demonstrated in our study population. The chronic low-grade pro-inflammatory state in patients with type 2 diabetes is often associated with a hypercoagulable state, increased endothelial dysfunction, oxidative stress, and ultimately onset or progression of micro- and macrovascular diabetes complications [34–38].

Several studies in Caucasian and Asian populations have documented an association between low serum vitamin D levels and pancreatic beta-cell dysfunction and insulin resistance [9–12, 39]. On the contrary, we did not observe any association between vitamin D deficiency and insufficiency and markers of pancreatic beta-cell dysfunction and insulin resistance in our study. This indicates that a low serum vitamin D status may not be involved in the pathogenesis of type 2 diabetes in the adult Ugandan population.

With exception of a study performed in Western Kenya that reported a correlation between low serum vitamin D levels and reduced pancreatic beta-cell function as assessed by oral disposition index [26], similar studies performed in other adult African populations (Nigerian and Ghanaian) with type 2 diabetes have not reported an association between insulin resistance, pancreatic beta-cell dysfunction, and low serum vitamin D status [28, 29], further confirming that low serum vitamin D status may not play a role in the pathogenesis of type 2 diabetes in some black African populations.

**Conclusion**

Vitamin D deficiency and insufficiency were highly prevalent in our adult population with recently diagnosed diabetes and were associated with increased circulating concentrations of specific pro-inflammatory cytokines. The absence of an association between pancreatic beta-cell function, insulin resistance, and suboptimal serum vitamin D concentrations may suggest that the low serum vitamin D levels do not play a key role in the pathophysiology of type 2 diabetes in our adult Ugandan population. The long-term clinical implications of increased circulating concentrations of the pro-inflammatory cytokines in adult Ugandan patients with vitamin D deficiency and insufficiency, especially its association with reduction in the pancreatic beta-cell function and onset and/or progression of micro/macrovascular diabetes complications, needs to be fully investigated.

**Fig. 1** Box plots showing the differences in the circulating log concentrations of IL-6 and IL-8 between participants with vitamin D deficiency, vitamin D insufficiency, and normal vitamin D status.
Abbreviations
BIA: Bioimpedance analysis; BMI: Body mass index; FBG: Fasting blood glucose; Hba1c: Glycated haemoglobin; HC: Hip circumference; HOMA2-IR: Homeostatic model assessment 2-insulin resistance; HOMA2-%B: Homeostatic model assessment 2-beta-cell function; IGI: Insulinogenic index; IQR: Interquartile range; IL: Interleukin; SSA: sub-Saharan Africa; Th1: T-helper 1; Th-7: T-helper 7; WC: Waist circumference, WHR-waist: Hip circumference ratio.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12902-022-01148-7.

Additional file 1. Vitamin D study dataset.

Acknowledgements
We would like to express our gratitude to the entire study research team and all the study participants who consented to join the study.

Authors’ contributions
DK oversaw the entire data collection process and data interpretation, and wrote the initial draft of the manuscript. IS performed the statistical analysis, and data interpretation, and reviewed all the versions of the manuscript. PB, JKL, and WL contributed to the data interpretation, and discussion, and reviewed all the versions of the manuscript. All the authors read and approved the final draft of the manuscript.

Funding
This study was supported by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement, through a strategic award (Project Reference: MC_UP_1204/16).

Availability of data and materials
All data generated or analysed during this study are included in this published article (and its supplementary information files).

Declarations
Ethics approval and consent to participate
The study was approved by the Research Ethics Committee of the Uganda Virus Research Institute (GC/127/18/05/650) and the Uganda National Council of Science and Technology (HS 2431). All participating study sites offered administrative approval before the initiation of the study. All study participants recruited into the study offered written informed consent.

Consent for publication
Not applicable.

Competing interests
All the authors report no conflict of interest.

Author details
1 Non-communicable Diseases Program, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, PO BOX 49, Plot 51-59, Nakivubo Road, Entebbe, Uganda. 2 Department of Non-Communicable Diseases Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK. 3 Clinical Diagnostics Laboratory Services, Medical Research Council/Uganda Virus Research Institute, and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda. 4 Department of Medicine, Mengo Hospital, Kampala, Uganda.

Received: 22 February 2022 Accepted: 9 September 2022
Published online: 15 September 2022

References
1. Amrein K, Scherker M, Hoffmann M, Neuwersch-Sommeregger S, Kostenberger M, Tmavalerisha A, Martucci G, Pilz S, Malle O. Vitamin D deficiency 2.0: an update on the current status worldwide. Eur J Clin Nutr. 2020;74(11):1498–513.
2. Roth DE, Abrams SA, Aloja J, Bergeron G, Bourassa MW, Brown KH, Calvo MS, Cashman KD, Combs G, De-Regil LM, et al. Global prevalence and disease burden of vitamin D deficiency: a roadmap for action in low- and middle-income countries. Ann N Y Acad Sci. 2018;1430(1):44–79.
3. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(13):266–81.
4. Mogire RM, Mutua A, Kimita W, Kamau A, Bejon P, Pettifor JM, Adeyemo A, Williams TN, Atkinson SH. Prevalence of vitamin D deficiency in Africa: a systematic review and meta-analysis. Lancet Glob Health. 2020;8(1):e134–42.
5. Prentice A, Schoenmakers I, Jones KS, Jaujo LMA, Goldberg GR. Vitamin D Deficiency and Its Health Consequences in Africa. Clin Rev Bone Miner Metab. 2009;7(1):94–106.
6. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr. 2008;88(2):491s–9s.
7. Mezza T, Muscogiuri G, Sonce GP, Proietta A, Salomone E, Pontecorvi A, Giacca A. Vitamin D deficiency: a new risk factor for type 2 diabetes. Ann Nutr Metab. 2012;61(4):337–48.
8. Mathieu C, Gysens C, Gualtieri A, Bouillon R. Vitamin D and diabetes. Diabetologia. 2005;48(7):1247–57.
9. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79(5):820–5.
10. Zhao H, Tang Y, Zheng C, Ren L, Song G. Vitamin D status is independently associated with insulin resistance in patients with type 2 diabetes mellitus. Risk Manag Healthc Policy. 2021;14:1393–9.
11. Zhao H, Zheng C, Zhang M, Chen S. The relationship between vitamin D status and islet function in patients with type 2 diabetes mellitus. BMC Endocr Disord. 2021;21(1):203.
12. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care. 2004;27(11):2813–8.
13. Dawson-Hughes B, Staeh M A, Knowler WC, Nelson J, Vickery EM, LeBlanc ES, Neff LM, Park J, Pittas AG. Intratrophic exposure to vitamin D and new-onset diabetes among adults with prediabetes: a secondary analysis from the Vitamin D and type 2 Diabetes (D2d) study. Diabetes Care. 2020;43(1):2916–22.
14. Mohammadi S, Hajhashemy Z, Saneei P. Serum vitamin D levels in relation to type-2 diabetes and prediabetes in adults: a systematic review and dose-response meta-analysis of epidemiologic studies. Crit Rev Food Sci Nutr. 2021;1–21.
15. Shotton S, Herder C, Rothenbercher D, Perna L, Müller H, Brenner H. Serum 25-hydroxyvitamin D levels and incident diabetes mellitus type 2: a competing risk analysis in a large population-based cohort of older adults. Eur J Epidemiol. 2013;28(3):267–75.
16. Xiao Y, Wei L, Xiong X, Yang M, Sun L. Association between vitamin D status and diabetic complications in patients with type 2 diabetes mellitus: a cross-sectional study in Hunan China. Front Endocrinol (Lausanne). 2020;11:56738.
17. Ahmed LHM, Butler AE, Dargham SR, Latif A, Ahmed EA, Hassan A, Atkin SL. Relationship between total vitamin D metabolites and complications in patients with type 2 diabetes. Biomed Res. 2021;14(1):18–18.
18. WHO. Report of a WHO/IDF Consultation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. 2006. https://www.who.int/diabetes/publications/Definition%20of%20Diagnosis%20of%20Diabetes%20Mellitus.pdf. Accessed 11 June 2021.
19. Cavalier E, Lukas P, Cine Y, Peeters S, Carlisi A, Le Goff C, Gadisseur R, Delanaye P, Souberbielle JC. Evaluation of automated immunoassays for 25(OH)-vitamin D determination in different critical populations before and after standardization of the assays. Clin Chim Acta. 2014;431:60–5.
20. Emmen JM, Weidlers JP, Boer AK, van den Ouwereland JM, Vader HL. The new Roche vitamin D total assay: fit for its purpose? Clin Chem Lab Med. 2012;50(1):1–4.
21. Freeman J, Wilson K, Spears R, Shalhoub V, Sibley P. Performance evaluation of four 25-hydroxyvitamin D assays to measure 25-hydroxyvitamin D2. Clin Biochem. 2015;48(16–17):1097–104.

22. Trimble F, Rotundo S, Armilli S, Memmi S, Luca F, Montenegro N, Antico GC, Gaeta A, Gaetano M, Galato F, et al. Serum 25-hydroxyvitamin D measurement: comparative evaluation of three automated immunoassays. Pract Lab Med. 2021;26:e00251.

23. The Homeostasis Model Assessment (HOMA) 2 calculator. https://www.dtu.ox.ac.uk/homacalculator/. Accessed on 01 June 2020.

24. Cersosimo E, Solis-Herrera C, Trautmann ME, Malloy J, Triplitt CL. Assessment of pancreatic β-cell function: review of methods and clinical applications. Curr Diabetes Rev. 2014;10(1):2–42.

25. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911–30.

26. Said J, Latagi D, Kinama A, Odouor C. Beta cell function, insulin resistance and vitamin D status among type 2 diabetes patients in Western Kenya. Sci Rep. 2021;11(1):4084.

27. Karau PB, Kinra B, Amayo E, Joshi M, Ngare S, Muriira G. The prevalence of vitamin D deficiency among patients with type 2 diabetes seen at a referral hospital in Kenya. Pan Afr Med J. 2019;34:38–38.

28. Anyanwu AC, Olopa O, Onung SI, Odensiyi IA, Coker HAB, Fasanmade OA, Ohwovoriole AE. Serum vitamin D levels in persons with type 2 diabetes mellitus in Lagos. Nigeria Int J Diabetes Clin Res. 2020;7:133.

29. Fondjo LA, Owiredu WKBA, Sakyi SA, Laing EF, Adotey-Kwoffe MA, Antoh EO, Detoh E. Vitamin D status and its association with insulin resistance among type 2 diabetics: A case-control study in Ghana. PLoS ONE. 2017;12(4):e0175388.

30. de Souza WN, Nordhe MM, Oki E, Rogero MM, Marchionni DM, Fisberg RM, Martins LA. Association between 25-hydroxyvitamin D and inflammatory biomarker levels in a cross-sectional population-based study, São Paulo Brazil. Nutr Res. 2016;36(1):1–8.

31. Ganji V, Tangpricha V, Zhang X. Serum Vitamin D Concentration ≥75 nmol/L Is Related to Decreased Cardiometabolic and Inflammatory Biomarkers, Metabolic Syndrome, and Diabetes, and Increased Cardiorespiratory Fitness in US Adults. Nutrients. 2020;12(3):730.

32. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys. 2000;374(2):334–8.

33. Lemire JM. Immunomodulatory actions of 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol. 1995;53(1–6):599–602.

34. Donate-Correa J, Ferrer CM, Sánchez-Quintana F, Pérez-Castro A, González-Luis A, Martín-Núñez E, Mora-Fernández C, Navarro-González JF. Inflammatory cytokines in diabetic kidney disease: pathophysiologic and therapeutic implications. Front Med. 2021;7:628289.

35. Navarro JF, Mora C. Role of inflammation in diabetic complications. Nephrol Dial Transplant. 2005;20(12):2601–4.

36. Quevedo-Martinez JU, Garfias Y, Jiménez J, García O, Venegas D, Bautista de Lucio VM. Pro-inflammatory cytokine profile is present in the serum of Mexican patients with different stages of diabetic retinopathy secondary to type 2 diabetes. BMJ Open Ophthalmol. 2021;6(1):e000717.

37. Randeria SN, Thomson GJA, Nell TA, Roberts T, Pretorius E. Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation. Cardiovasc Diabetol. 2019;18(1):72.

38. Turtle HA, Davis-Gorman G, Goldman S, Copeland JC, McDonagh PF. Proinflammatory cytokines are increased in type 2 diabetes mellitus in women with cardiovascular disease. J Diabetes Compl. 2004;18(6):343–51.

39. Szymczak-Pajor I, Siwińska A. Analysis of Association between vitamin D deficiency and insulin resistance. Nutrients. 2019;11(1):794.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.